n°190

February 2018

Issue Contents
Editorial

Free  Misleading health reports in the mainstream media

p.31

Marketing Authorisations

Injectable methotrexate and ectopic pregnancy

p.33-37
An alternative to surgery but with the risks of a cytotoxic drug, teratogenic in the case of short delay before conception

Pembrolizumab (Keytruda°) monotherapy and me­tastatic or inoperable lung cancer

p.38-39
Encouraging results in first-line treatment need to be confirmed

Palbociclib (Ibrance°) and inoperable or metastatic breast cancer

p.40
Unfavourable harm-benefit balance

INN Common stem: -piprazole

p.40

Adverse Effects

Drug-induced tremor

p.41-44
Sometimes a sign of overdose or withdrawal

Levothyroxine: predictable disorders caused by a change in formulation

p.45-46

Reviews

COPD: a role for long-term azithromycin?

p.47-49
Uncertain benefits, established harms

Advanced melanoma

p.50
Risks from combining two immunostimulants

Free  Localised prostate cancer

p.51
Immediate treatment, or not: 10-year results

Outlook

A pictogram on boxes of teratogenic or fetotoxic drugs

p.52-53
An opportunity to discuss the dangers of drugs during pregnancy

Free  Conditional marketing authorisation: based on very little data

p.54

Free  Virtual evaluation

p.55
Increased threat to patient safety

Masthead

Free  Masthead

p.30

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe